 |
| |
| Oct-30-19 | Downgrade |
Piper Jaffray |
Neutral → Underweight |
$9 → $6 |
|
| Aug-01-19 | Initiated |
H.C. Wainwright |
Buy |
$16 |
|
| Jun-11-19 | Initiated |
Barclays |
Overweight |
$19 |
|
| Mar-20-19 | Initiated |
SunTrust |
Hold |
|
|
| Dec-14-18 | Reiterated |
B. Riley FBR |
Buy |
$29 → $20.50 |
|
| Nov-06-18 | Downgrade |
JP Morgan |
Neutral → Underweight |
|
|
| Jun-15-18 | Downgrade |
Janney |
Buy → Neutral |
|
|
| May-21-18 | Resumed |
Leerink Partners |
Mkt Perform |
|
|
| Mar-14-18 | Reiterated |
B. Riley FBR, Inc. |
Neutral |
$16 → $23 |
|
| Feb-15-18 | Upgrade |
Janney |
Neutral → Buy |
|
|
| Dec-07-17 | Initiated |
B. Riley FBR, Inc. |
Neutral |
$16 |
|
| Oct-23-17 | Initiated |
Piper Jaffray |
Neutral |
$18 |
|
| Sep-08-17 | Initiated |
Morgan Stanley |
Overweight |
$26 |
|
| Jan-11-17 | Downgrade |
Needham |
Buy → Hold |
|
|
| Jan-10-17 | Downgrade |
Leerink Partners |
Outperform → Mkt Perform |
|
|
| Jan-09-17 | Downgrade |
Raymond James |
Mkt Perform → Underperform |
|
|
| Oct-27-16 | Initiated |
Needham |
Buy |
$40 |
|
| May-09-16 | Reiterated |
Deutsche Bank |
Hold |
$42 → $35 |
|
| May-04-16 | Downgrade |
Raymond James |
Outperform → Mkt Perform |
|
|
| Jan-21-16 | Initiated |
Barclays |
Equal Weight |
$32 |
|
|
|
| Dec-02-19 08:20AM | Those Who Purchased AMAG Pharmaceuticals (NASDAQ:AMAG) Shares Five Years Ago Have A 74% Loss To Show For It Simply Wall St. |
| Dec-01-19 09:30AM | Why Is AMAG Pharmaceuticals (AMAG) Up 9.7% Since Last Earnings Report? Zacks |
| Nov-26-19 09:19AM | Is the Options Market Predicting a Spike in AMAG Pharmaceuticals (AMAG) Stock? Zacks |
| Nov-19-19 04:54PM | Teva, Bausch Could Be Next to File for Bankruptcy GuruFocus.com |
| Nov-16-19 08:18AM | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AMAG Pharmaceuticals, Inc. - AMAG ACCESSWIRE |
| Nov-13-19 02:14PM | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AMAG Pharmaceuticals, Inc. - AMAG GlobeNewswire +5.21% |
| 08:00AM | AMAG Pharmaceuticals to Present at Upcoming Investor Conferences GlobeNewswire |
| Nov-07-19 05:44PM | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AMAG Pharmaceuticals, Inc. - AMAG GlobeNewswire |
| 11:44AM | Hedge Funds Are Still Bullish On AMAG Pharmaceuticals (AMAG) Insider Monkey |
| Nov-06-19 06:18AM | AMAG Sees Hammer Chart Pattern: Time to Buy? Zacks |
| Nov-05-19 03:35AM | Edited Transcript of AMAG earnings conference call or presentation 1-Nov-19 12:00pm GMT Thomson Reuters StreetEvents |
| Nov-04-19 11:18AM | AMAG Q3 Loss Wider Than Expected, Revenues Lag Estimates Zacks -5.84% |
| Nov-01-19 12:25PM | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AMAG Pharmaceuticals, Inc. - AMAG GlobeNewswire |
| 09:15AM | AMAG Pharmaceuticals (AMAG) Reports Q3 Loss, Lags Revenue Estimates Zacks |
| 07:00AM | AMAG Pharmaceuticals Announces Third Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire |
| Oct-31-19 11:36AM | The Zacks Analyst Blog Highlights: Alexion, Amgen, Gilead and AMAG Zacks -6.23% |
| 10:55AM | Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AMAG Pharmaceuticals, Inc. (AMAG) ACCESSWIRE |
| Oct-30-19 04:23PM | Biotech Dives After Panel Votes To Pull Its Drug Following Failed Test Investor's Business Daily -22.36% |
| 10:56AM | Biotech Stock Roundup: Q3 Earnings Beat at ALXN & AMGN, Pipeline Updates & More Zacks |
| 10:15AM | What's in Store for GW Pharmaceuticals (GWPH) in Q3 Earnings? Zacks |
| 09:20AM | AMAG Pharmaceuticals Falls 25% After FDA Recommends Removing Makena From The Market Benzinga |
| Oct-29-19 09:40PM | AMAG Reports on FDA Advisory Committee Meeting for Makena® (Hydroxyprogesterone Caproate Injection) GlobeNewswire |
| 05:05PM | FDA committee votes to pull labor-halting drug from market American City Business Journals |
| 10:29AM | AMAG Pharmaceuticals, Inc. (AMAG) Shares March Higher, Can It Continue? Zacks |
| 10:25AM | Is a Beat in Store for Amarin (AMRN) This Earnings Season? Zacks |
| 07:03AM | AMAG Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee Meeting to Discuss the Results of the Makena PROLONG Trial GlobeNewswire |
| Oct-28-19 04:21PM | This Biotech Stock Popped But Could The FDA Pull Its Key Drug? Investor's Business Daily +8.73% |
| 06:04AM | Proxy fights reach 'frightening' level in life sciences, other industries, top attorney says American City Business Journals |
| Oct-27-19 12:56PM | The Week Ahead In Biotech: Adcom Test For Agile; Pfizer, Merck Lead Earnings Benzinga |
| Oct-25-19 10:30AM | AMAG Pharmaceuticals (AMAG) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks +13.83% |
| 10:19AM | AMAG Pharmaceuticals Announces the Publication of the PROLONG Trial Evaluating 17-OHPC in the American Journal of Perinatology GlobeNewswire |
| Oct-24-19 08:00AM | AMAG Pharmaceuticals to Host Third Quarter 2019 Financial Results Conference Call and Webcast on Friday, November 1, 2019 at 8:00 a.m. ET GlobeNewswire -9.27% |
| Oct-11-19 08:00AM | AMAG Pharmaceuticals Announces the Publication of the Phase 3 Vyleesi (Bremelanotide Injection) Data in Obstetrics & Gynecology GlobeNewswire |
| Oct-08-19 08:45AM | UPDATE 2-Amag settles with activist Caligan, adds two board directors Reuters |
| 08:14AM | Amag appoints activist investor Caligan's nominees to board Reuters |
| 08:00AM | AMAG Pharmaceuticals Announces Settlement Agreement with Caligan Partners LP GlobeNewswire |
| Sep-28-19 09:05AM | Here's Why AMAG Pharmaceuticals (NASDAQ:AMAG) Can Afford Some Debt Simply Wall St. |
| Sep-26-19 08:00AM | Caligan Partners Issues Letter to AMAG Shareholders Business Wire -5.42% |
| Sep-25-19 08:00AM | AMAG Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference GlobeNewswire |
| Sep-23-19 08:00AM | AMAG Files Definitive Consent Revocation Statement and Sends Letter to Shareholders GlobeNewswire |
| Sep-20-19 08:44AM | UPDATE 2-Camber Capital to discuss Amag's board composition with shareholders Reuters +8.54% |
| 08:20AM | Camber Capital says Amag Pharma's shares undervalued, seeks changes Reuters |
| Sep-16-19 08:00AM | Caligan Partners Launches Consent Solicitation Process and Sends Letter to AMAG Shareholders Business Wire |
| Sep-12-19 08:00AM | AMAG Sends Letter to Shareholders GlobeNewswire |
| Sep-06-19 09:31AM | Why Is AMAG Pharmaceuticals (AMAG) Up 27.3% Since Last Earnings Report? Zacks |
| Sep-05-19 06:24AM | Activist investor pushes for ex-Goop CEO, others to join board of Waltham drugmaker Amag American City Business Journals |
| Sep-04-19 05:56PM | AMAG Urges Stockholders to Take No Action on Caligan Partners Consent Solicitation Materials GlobeNewswire +8.19% |
| 09:45AM | Activist Investor Seek Four Board Seats at Amag Pharmaceuticals Bloomberg |
| Aug-30-19 09:29PM | Edited Transcript of AMAG earnings conference call or presentation 7-Aug-19 12:00pm GMT Thomson Reuters StreetEvents |
| Aug-27-19 08:00AM | AMAG Pharmaceuticals Announces Commercial Availability of Vyleesi (Bremelanotide Injection) GlobeNewswire |
| Aug-20-19 08:00AM | AMAG Pharmaceuticals Announces Grant of Inducement Awards Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire |
| Aug-16-19 10:42AM | Palatin's (PTN) to Report Q4 Earnings: What's in the Cards? Zacks |
| 06:20AM | Gene therapies to test FDA's approach to regulating drugs after launch, experts say American City Business Journals |
| Aug-15-19 02:23PM | [video]New York Investment Firm Discloses 10.3% Amag Stake, May Propose Changes TheStreet.com -6.25% |
| Aug-14-19 01:39PM | Have Insiders Been Buying AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Shares? Simply Wall St. |
| Aug-13-19 11:42AM | Jim Cramer Shares His Thoughts On Delta Air Lines, Okta And More Benzinga |
| 08:00AM | AMAG PHARMACEUTICALS ANNOUNCES GRANT OF INDUCEMENT AWARDS UNDER NASDAQ LISTING RULE 5635(c)(4) GlobeNewswire |
| Aug-12-19 04:00PM | Why AMAG Pharmaceuticals Stock Jumped Today Motley Fool +14.19% |
| Aug-09-19 09:41AM | AMAG Pharmaceuticals Inc (AMAG) Q2 2019 Earnings Call Transcript Motley Fool +11.52% |
| Aug-08-19 11:20AM | AMAG Q2 Loss Widens, Sales Lag Estimates, 2019 Guidance Cut Zacks +5.09% |
| Aug-07-19 03:00PM | What's Behind AMAG Pharmaceuticals' Horrible Q2 Results Motley Fool -9.05% |
| 08:35AM | AMAG Pharmaceuticals (AMAG) Reports Q2 Loss, Misses Revenue Estimates Zacks |
| 07:00AM | AMAG Pharmaceuticals Announces Second Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire |
| Aug-06-19 12:50PM | UPDATE 1-Amag's female libido injectable therapy to sell at $899 Reuters +9.21% |
| 12:43PM | Amag's female libido injectable therapy to sell at $899 Reuters |
| 12:21PM | Amag's female libido injectable therapy to sell at $899 Reuters |
| Jul-31-19 10:36AM | AMAG Pharmaceuticals (AMAG) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks |
| Jul-29-19 08:00AM | AMAG Pharmaceuticals to Host Second Quarter 2019 Financial Results Conference Call and Webcast on Wednesday, August 7, 2019 at 8:00 a.m. ET GlobeNewswire |
| Jul-25-19 10:33AM | Will AMAG Pharmaceuticals (AMAG) Report Negative Q2 Earnings? What You Should Know Zacks |
| Jul-23-19 09:29AM | AMAG (AMAG) to Report Q2 Earnings: What's in the Cards? Zacks |
| Jul-09-19 03:07PM | Calculating The Intrinsic Value Of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Simply Wall St. |
| Jul-04-19 08:35AM | Alexion's Ultomiris Receives EU Approval for PNH in Adults Zacks |
| Jun-28-19 01:03PM | Largest Insider Trades of the Week GuruFocus.com |
| Jun-27-19 12:55PM | Heres What Hedge Funds Think About AMAG Pharmaceuticals, Inc. (AMAG) Insider Monkey |
| Jun-26-19 08:37AM | Biotech Stock Roundup: Vertex, AMAG Drugs Get FDA Nod, Conatus Study Fails & More Zacks |
| Jun-25-19 03:49PM | Why Palatin Technologies Stock Dropped as Much as 21.5% Today Motley Fool |
| 02:00PM | How Raleigh's Sprout can benefit from FDA's approval of another female sexual disorder drug American City Business Journals |
| Jun-24-19 05:45PM | AMAG's Vyleesi Gets FDA NOD for Women with Low Sexual Desire Zacks |
| 04:19PM | Palatin Jumps Then Pulls Back After FDA Clears Sexual-Desire Drug for Women TheStreet.com |
| 01:58PM | Another Womens Libido Drug, Vyleesi, Won FDA Approval. Stock Investors Arent Happy. Barrons.com |
| 08:03AM | Palatin's stock rockets after FDA OK to market sexual desire disorder treatment MarketWatch |
| Jun-22-19 03:07PM | The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs Benzinga |
| Jun-21-19 05:41PM | AMAG stock rallies on FDA approval for drug to increase women's sex drive MarketWatch |
| 05:37PM | Amags plan to bypass female libido drug pitfalls? Social media. American City Business Journals |
| 05:23PM | AMAG Pharmaceuticals Announces FDA Approval of Vyleesi (Bremelanotide Injection) for Acquired, Generalized Hypoactive Sexual Desire Disorder (HSDD) in Premenopausal Women GlobeNewswire |
| Jun-20-19 09:00AM | All You Need to Know About AMAG Pharmaceuticals (AMAG) Rating Upgrade to Buy Zacks |
| Jun-10-19 09:39AM | TherapeuticsMD Enters Agreement to Market Drugs Outside US Zacks |
| Jun-06-19 09:31AM | AMAG Pharmaceuticals (AMAG) Down 8.9% Since Last Earnings Report: Can It Rebound? Zacks |
| Jun-05-19 03:45PM | AMAG Pharmaceuticals Could Be Cut in Half Even From Here - Avoid TheStreet.com |
| May-29-19 08:00AM | AMAG Pharmaceuticals to Present at Jefferies 2019 Global Healthcare Conference GlobeNewswire |
| May-20-19 03:15PM | Is AMAG Pharmaceuticals, Inc.'s (NASDAQ:AMAG) Balance Sheet A Threat To Its Future? Simply Wall St. |
| 05:21AM | New Strong Sell Stocks for May 20th Zacks |
| May-17-19 08:00AM | AMAG Pharmaceuticals to Host Analyst Day on May 22, 2019 in New York GlobeNewswire |
| May-13-19 09:07PM | Edited Transcript of AMAG earnings conference call or presentation 7-May-19 12:00pm GMT Thomson Reuters StreetEvents |
| May-10-19 10:31AM | New Strong Sell Stocks for May 10th Zacks |
| May-09-19 07:48PM | Is AMAG Pharmaceuticals, Inc. (AMAG) A Good Stock To Buy? Insider Monkey |
| 07:15PM | Amag Pharmaceuticals Inc (AMAG) President & CEO William K Heiden Bought $107,000 of Shares GuruFocus.com |
| 06:57AM | AMAG Q1 Loss Wider Than Expected, Revenues Lag Estimates Zacks |
| May-08-19 07:53AM | The Daily Biotech Pulse: Daiichi's Positive Breast Cancer Trial, Supernus Slumps, Axovant Reverse Split Benzinga +5.56% |
| May-07-19 01:23PM | AMAG Pharmaceuticals Inc (AMAG) Q1 2019 Earnings Call Transcript Motley Fool -12.28% |
|
|
|
|
| AMAG Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. The company's products candidates include Vyleesi (bremelanotide), an auto-injector device for the treatment of hypoactive sexual desire disorder in pre-menopausal women; AMAG-423, a polyclonal antibody in development for the treatment of severe preeclampsia in pregnant women; and Ciraparantag, an anticoagulant reversal agent for the treatment of oral anticoagulants or low molecular weight heparin. It sells Feraheme to authorized wholesalers and specialty distributors. The company has a license agreement with Endoceutics, Inc., Palatin Technologies, Inc., Velo Bio LLC, Perosphere Pharmaceuticals Inc., Antares Pharma, Inc., and Abeona Therapeutics, Inc. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Camber Capital Management LP | 10% Owner | Aug 09 | Buy | 8.97 | 30,000 | 268,996 | 4,390,000 | Aug 09 03:41 PM | | ARMISTICE CAPITAL, LLC | 10% Owner | Aug 07 | Buy | 7.43 | 40,000 | 297,200 | 240,000 | Aug 09 05:05 PM | | ARMISTICE CAPITAL, LLC | 10% Owner | Aug 07 | Buy | 7.32 | 260,000 | 1,903,200 | 4,060,000 | Aug 09 05:05 PM | | Camber Capital Management LP | 10% Owner | Aug 07 | Buy | 7.78 | 355,000 | 2,760,796 | 4,360,000 | Aug 09 03:41 PM | | ARMISTICE CAPITAL, LLC | 10% Owner | Jun 27 | Buy | 9.47 | 20,000 | 189,400 | 200,000 | Jun 27 06:29 PM | | ARMISTICE CAPITAL, LLC | 10% Owner | Jun 27 | Buy | 9.52 | 44,000 | 418,880 | 3,800,000 | Jun 27 06:29 PM | | ARMISTICE CAPITAL, LLC | 10% Owner | Jun 26 | Buy | 9.13 | 120,000 | 1,095,600 | 3,756,000 | Jun 27 06:29 PM | | ARMISTICE CAPITAL, LLC | 10% Owner | Jun 25 | Buy | 8.86 | 55,000 | 487,050 | 180,000 | Jun 27 06:29 PM | | ARMISTICE CAPITAL, LLC | 10% Owner | Jun 25 | Buy | 8.59 | 259,016 | 2,224,947 | 3,636,000 | Jun 27 06:29 PM | | Krop Julie | Chief Medical Officer | May 28 | Buy | 9.91 | 10,000 | 99,100 | 81,399 | May 29 04:27 PM | | HEIDEN WILLIAM K | President & CEO | May 09 | Buy | 10.70 | 10,000 | 107,000 | 490,056 | May 09 04:16 PM | | Bolgiano Elizabeth Scott | Chief Human Resources Officer | May 09 | Buy | 10.93 | 5,000 | 54,650 | 74,847 | May 09 04:14 PM | | Vittiglio Joseph | EVP, General Counsel | Mar 07 | Sale | 14.01 | 1,425 | 19,964 | 78,955 | Mar 11 04:41 PM |
|
|
|
|
|
|
